Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results GlobeNewswire August 13, 2025 Reported positive topline data from Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all […]